InvestWiser

Mendus AB (publ)

IMMUNasdaq StockholmHealthcareMarket value 223 m SEK
3.60SEK −5.0%
last day · Price as of 18 November 2026

The answer first

Does Mendus beat the market?

No, Mendus has not beaten the market over the last year.

Mendus−35.0%Stockholm (OMXSGI)+17.6%
  • The ranking · Quality, value and trend combined

    Better than 50% of Nordic stocks

    • Quality83
    • Value60
    • Trend13

    No. 59 of 195 in healthcare

Max for seven days

Follow Mendus with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Mendus

From today, at a price of 3.60 SEK. Write why you follow Mendus, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Mendus

Your first answer is free, no account needed.

Do you own Mendus, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Mendus and a few more. Free, no card.

Past year against the exchange and Super Stock
Mendus−35.0%Stockholm (OMXSGI)+17.6%Super Stock+44.6%
17 November 202518 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Mendus has fallen 35.0% over the past year, including dividends.
  • Overall, Mendus ranks better than 50% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 94.5%. The price is 99.5% below its peak now.

What do analysts think of Mendus?

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

50

Quality, value and trend together. Better than 50% of Nordic stocks.

No. 59 of 195 in healthcare

Quality83
The company · Fundamentals: the accounts

High A solid company: it earns well on its money and has healthy finances.

No. 44 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity0.07
  • Asset turnoverSales divided by everything the company owns0.00
  • Return on equityProfit divided by equity−20.3%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value60
The price · Valuation: the multiples

Medium Fair price: about the same as a typical Nordic stock.

No. 27 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50

  • P/BPrice divided by equity0.4
  • P/SPrice divided by sales232.0
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend13
The share price · Technical: the price trend

Low Headwind in the share price: it has done worse than most over the last year.

No. 149 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−47.4%
  • 6 months−35.7%
  • 9 months−24.8%
  • 12 months−35.0%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−29.7%
3 years, per year
−26.3%
5 years, per year
−46.7%
10 years, per year
−37.7%
Largest fall, 3 years
−94.5%
From a peak to the bottom
From the peak now
−99.5%
How far the price is from the peak
Volatility, 1 year
69.8%
How much the price swings over a year
Beta, 1 year
0.50
How much the price moves when the market moves

Return with dividends reinvested.

The funds that own Mendus

2 funds we follow own Mendus. The share is how much of the fund the stock makes up.

  • Sweden2

From the funds' latest known holdings.

About Mendus

Mendus AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 27 employees.

Mendus AB (publ), a biopharmaceutical company, develops immunotherapies for the treatment of myeloid blood cancers. The company's lead product is vididencel (DCP-001), which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia (AML); Phase 2b CADENCE clinical trial to treat AML; phase 1 clinical trial for the treatment of Vital-CML; and phase 2a clinical trial for the treatment of VITAL-TFR2. It has strategic alliance with NorthX Biologic to support large-scale manufacturing and commercial launch of vididencel. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022.

See the full analysis of Mendus.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market